Literature DB >> 34295561

Correlation analysis of tumor mutation burden of hepatocellular carcinoma based on data mining.

Weijie Zhou1, Dalang Fang2, Yongfei He3, Jie Wei1.   

Abstract

BACKGROUND: The aim of this study was to determine the relationship between tumor mutation burden (TMB) and prognosis of patients with hepatocellular carcinoma (HCC), and to explore the differential expression of genes in HCC by TMB and the relationship between immune cells, TMB, and HCC.
METHODS: Somatic variation data, gene transcriptional expression data and clinical information of patients with HCC were obtained from cancer genome map (TCGA) database. Analyze the characteristics of the gene mutation data of the sample, divide the high and low TMB groups and draw the survival curve at the same time, carry on the difference analysis to the gene of TMB, further carry on the univariate Cox regression analysis and Lasso regression analysis and construct the clinical model. Download the dataset GSE14520, from the Gene Expression Omnibus (GEO) database to verify the genes of the prognostic model. The differential genes were analyzed by gene ontology (GO) enrichment analysis and Kyoto encyclopedia of genes and genomes by (KEGG) enrichment analysis. Then the relative abundance of 22 immune cell types in HCC and normal control samples was calculated. Finally, the correlation between the scores of immune cells and Risk model was analyzed.
RESULTS: Tumor protein p53 (TP53), catenin1 (CTNNB1), titin (TTN), mucin 16 (MUC16), and albumin (ALB) are the most common top 5 mutations in HCC. The prognosis of high level TMB group is worse than that of low TMB group. A total of 122 differentially expressed genes were screened by differential analysis of TMB genes. SQSTM1, ME1, BAMBI and PTTG1 are independent risk factors for poor prognosis of HCC. GO and KEGG analysis showed that the differential genes were mainly in extracellular matrix and immune response. There were significant differences in the distribution of Macrophages M0 and T cells CD4 native cells between HCC and normal tissues, which were correlated with the differential genes of TMB and correlated with prognosis.
CONCLUSIONS: There is a negative correlation between TMB and the prognosis of patients with HCC. TMB has an effect on the differential expression of genes in HCC cells and the distribution of immune cells in tumor tissues. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); immune, prognosis; tumor mutation burden (TMB)

Year:  2021        PMID: 34295561      PMCID: PMC8261312          DOI: 10.21037/jgo-21-259

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  50 in total

1.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors:  Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

Review 2.  Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.

Authors:  Samuel J Klempner; David Fabrizio; Shalmali Bane; Marcia Reinhart; Tim Peoples; Siraj M Ali; Ethan S Sokol; Garrett Frampton; Alexa B Schrock; Rachel Anhorn; Prasanth Reddy
Journal:  Oncologist       Date:  2019-10-02

3.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

Review 4.  Remodelling the extracellular matrix in development and disease.

Authors:  Caroline Bonnans; Jonathan Chou; Zena Werb
Journal:  Nat Rev Mol Cell Biol       Date:  2014-12       Impact factor: 94.444

5.  Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma.

Authors:  Hyung-Don Kim; Gi-Won Song; Seongyeol Park; Min Kyung Jung; Min Hwan Kim; Hyo Jeong Kang; Changhoon Yoo; Kijong Yi; Kyung Hwan Kim; Sukyeong Eo; Deok-Bog Moon; Seung-Mo Hong; Young Seok Ju; Eui-Cheol Shin; Shin Hwang; Su-Hyung Park
Journal:  Gastroenterology       Date:  2018-08-24       Impact factor: 22.682

6.  C-terminal-truncated HBV X promotes hepato-oncogenesis through inhibition of tumor-suppressive β-catenin/BAMBI signaling.

Authors:  Seok Lee; Mi-Jin Lee; Jun Zhang; Goung-Ran Yu; Dae-Ghon Kim
Journal:  Exp Mol Med       Date:  2016-12-02       Impact factor: 8.718

7.  BPIFB1 (LPLUNC1) inhibits radioresistance in nasopharyngeal carcinoma by inhibiting VTN expression.

Authors:  Fang Wei; Le Tang; Yi He; Yingfen Wu; Lei Shi; Fang Xiong; Zhaojian Gong; Can Guo; Xiayu Li; Qianjin Liao; Wenling Zhang; Qianxi Ni; Jia Luo; Xiaoling Li; Yong Li; Cong Peng; Xiang Chen; Guiyuan Li; Wei Xiong; Zhaoyang Zeng
Journal:  Cell Death Dis       Date:  2018-04-01       Impact factor: 8.469

8.  First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

Authors:  Neal Ready; Matthew D Hellmann; Mark M Awad; Gregory A Otterson; Martin Gutierrez; Justin F Gainor; Hossein Borghaei; Jacques Jolivet; Leora Horn; Mihaela Mates; Julie Brahmer; Ian Rabinowitz; Pavan S Reddy; Jason Chesney; James Orcutt; David R Spigel; Martin Reck; Kenneth John O'Byrne; Luis Paz-Ares; Wenhua Hu; Kim Zerba; Xuemei Li; Brian Lestini; William J Geese; Joseph D Szustakowski; George Green; Han Chang; Suresh S Ramalingam
Journal:  J Clin Oncol       Date:  2019-02-20       Impact factor: 44.544

Review 9.  Macrophages and hepatocellular carcinoma.

Authors:  Zhiqiang Tian; Xiaojuan Hou; Wenting Liu; Zhipeng Han; Lixin Wei
Journal:  Cell Biosci       Date:  2019-09-26       Impact factor: 7.133

10.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Authors:  Matthew D Hellmann; Luis Paz-Ares; Reyes Bernabe Caro; Bogdan Zurawski; Sang-We Kim; Enric Carcereny Costa; Keunchil Park; Aurelia Alexandru; Lorena Lupinacci; Emmanuel de la Mora Jimenez; Hiroshi Sakai; Istvan Albert; Alain Vergnenegre; Solange Peters; Konstantinos Syrigos; Fabrice Barlesi; Martin Reck; Hossein Borghaei; Julie R Brahmer; Kenneth J O'Byrne; William J Geese; Prabhu Bhagavatheeswaran; Sridhar K Rabindran; Ravi S Kasinathan; Faith E Nathan; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

View more
  1 in total

1.  Prognostic Signature and Tumor Immune Landscape of N7-Methylguanosine-Related lncRNAs in Hepatocellular Carcinoma.

Authors:  Wei Wei; Chao Liu; Meng Wang; Wei Jiang; Caihong Wang; Shuqun Zhang
Journal:  Front Genet       Date:  2022-07-22       Impact factor: 4.772

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.